Literature DB >> 6488165

Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.

R Ganapathi, D Grabowski, W Rouse, F Riegler.   

Abstract

Calmodulin inhibitors enhance cytotoxic effects of doxorubicin (DOX) in DOX-resistant (P388/DOX) P388 mouse leukemia cells by increasing cellular accumulation and retention of drug. In P388/DOX cells treated for 3 hr, cytotoxic effects (based on colony formation in soft agar) of daunorubicin (DAU) in the presence of trifluoperazine (TFP) were DAU concentration-dependent and enhanced 2- to 100-fold. Additionally, in the presence of TFP, on a molar basis, equitoxic doses of DAU were 4-fold lower than DOX for P388/DOX cells. However, in P388/DOX cells treated for 3 hr with other anthracyclines, except for a slight enhancement in the cytotoxic effects of aclacinomycin A (ACM) with TFP, colony formation in soft agar of cells treated with N-trifluoroacetyladriamycin-14-valerate (AD32) and N-trifluoroacetyladriamycin were similar in the absence and presence of TFP. In DOX-sensitive (P388/S) P388 mouse leukemia cells treated for 3 hr, some enhancement in the cytotoxic effects due to TFP were observed with DAU and DOX but not with ACM, AD32, or N-trifluoroacetyladriamycin. Although accumulation of ACM and AD32 in P388/S and P388/DOX cells was similar and unaffected by TFP, the retention of ACM but not AD32 was enhanced 1.5-fold only in TFP-treated P388/DOX cells. In contrast, DAU accumulation in P388/S cells was 4-fold higher than in similarly treated P388/DOX cells, and the 2- and 4-fold increase due to TFP in the accumulation and retention, respectively, of DAU in P388/DOX cells was not observed in P388/S cells. Results from this study indicate that in P388/DOX cells, the calmodulin inhibitor TFP is more effective with DAU than DOX, significantly less effective with ACM, and ineffective with AD32 and N-trifluoroacetyladriamycin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488165

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.

Authors:  K S Sridhar; A Krishan; T S Samy; R C Duncan; A Sauerteig; G V McPhee; M E Auguste; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.

Authors:  W M Holleran; M W DeGregorio; R Ganapathi; J R Wilbur; B A Macher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.

Authors:  S A Rosenthal; W N Hait
Journal:  Yale J Biol Med       Date:  1988 Jan-Feb

5.  N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Authors:  R Ganapathi; D Grabowski; T W Sweatman; R Seshadri; M Israel
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

6.  Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.

Authors:  J M Millot; T D Rasoanaivo; H Morjani; M Manfait
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

7.  Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells.

Authors:  Fang Huang; Xiao-Nan Wu; Jie Chen; Wen-Xiang Wang; Zu-Fu Lu
Journal:  Exp Ther Med       Date:  2014-04-03       Impact factor: 2.447

8.  Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.

Authors:  R Ganapathi; H Schmidt; D Grabowski; M Melia; N Ratliff
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

9.  Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

Authors:  A M Julia; H Roché; M Berlion; C Lucas; G Milano; J Robert; J P Bizzari; P Canal
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  Mechanisms regulating resistance to inhibitors of topoisomerase II.

Authors:  Ram N Ganapathi; Mahrukh K Ganapathi
Journal:  Front Pharmacol       Date:  2013-08-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.